Objectives: To evaluate the prevalence of rheumatologic manifestations in 76 patients with Chikungunya infection, during an epidemic occurred in 2016 in the city of Rio de Janeiro, Brazil.

Methods: To evaluate the prevalence of rheumatologic manifestations in 76 patients with Chikungunya infection, during an epidemic occurred in 2016 in the city of Rio de Janeiro, Brazil.

Results: Females were the most prevalent: 65 patients (85.5%); male sex: 11 (14.5%). The mean age of the patients was 57.17 years. The youngest at age 24 and the oldest 87 years old. The time between the onset of symptoms and the first consultation with a rheumatologist ranged from 11 days to the highest period of 40 weeks. Among articular symptoms, polyarthralgia occurred with higher prevalence (39 patients, 51.31%), affecting wrists, ankles, shoulders, knees and hands. Twenty six patients had arthritis (34.21%), Tendinopathy in 27 regions, being more common in shoulders, ankles and wrists and including De Quervain. Paresthesias occurred in 7 patients, prevailing carpal tunnel syndrome and one patient presented dactylitis. Symptoms persisted for months in all patients.

Conclusions: Chikungunya is an endemic disease in Brazil, with severe joint manifestations and chronic symptoms. Often there is delay in starting treatment with rheumatologist, resulting in worsening of the clinical picture.

REFERENCES:

- [1] Lima-Camara TN. Emerging arboviruses and public health challenges in Brazil. *Revista Saude Publica* 2016;50:36:2016.
- [2] Petersen LR, Powers AM. Chikungunya: epidemiology. *F1000 Faculty Reviews* 2016;5:82.
- [3] Rodriguez-Morales AJ, Gil-Restrepo AF, Ramirez-Jaramillo, et al. Chikungunya chronic inflammatory rheumatism: results from a retrospective follow-up study of 283 adult and child cases in La Virginia, Risaralda, Colombia. *F1000 Faculty Reviews* 2016;5:360.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6971

SAT0407

MYCOBACTERIAL INFECTIONS IN A RHEUMATOLOGY UNIT OF A TERTIARY HOSPITAL

M. Espinosa Malpartida¹, C. Ramos Giráldez¹, C. Merino Argumániz¹, O. Rusinovich², M. García Moreno³, C. Barbadillo Mateos¹, J. Campos Esteban¹, H. Godoy Tundidor¹, J. Sanz Sanz¹, C.M. Isasi², M. Jiménez Palop², J.L. Andreu Sánchez¹, L.F. Villa². ¹Rheumatology; ²H. U. Puerta de Hierro Majadahonda, Madrid, Spain; ³Microbiology, H. U. Puerta de Hierro Majadahonda, Madrid, Spain

Background: Many treatments for rheumatic diseases, especially the new ones such as anti-TNF or anti-IL6 therapies, are known to increase the risk of tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections.

Objectives: To determine the incidence of mycobacterial infections in patients of the rheumatology unit in our hospital.

Methods: We retrospectively reviewed the results of microbiological studies for the detection of mycobacteria requested for patients of the Rheumatology service in our hospital from January 1, 2008 to October 1, 2017. We reviewed the clinical histories of the patients in whom a positive result was obtained. Different clinical and microbiological parameters were collected: age, gender, type of sample, isolated germ, infection location, antimicrobial treatment, main basal disease and immunosuppressive treatment received at the time of sampling.

Results: We reviewed 719 samples from 311 patients. The 28 samples that were positive for mycobacteria corresponded to 16 patients (50% males, with a mean age of 58.6 years). *M. avium complex* (MAC) was isolated in 10 patients, *M. tuberculosis complex* (MTB) in 4 patients and *M. goodii* in two cases. Seven clinical infections occurred (5% of the total studied patients), 4 due to MTB and 3 to MAC. The predominant involvement was pulmonary (5 patients, one of them also with spondylodiscitis); one patient had infectious oligoarthritis with cutaneous involvement and another patient lymph node involvement. Six of the 7 patients with mycobacterial infection were receiving chronic treatment with prednisone (or equivalent dose of corticosteroids) >5 mg/day (85.71%). In two of them adalimumab was associated, and methotrexate in other two.

Conclusions: The incidence of mycobacterial infections in patients with rheumatic diseases has increased, coupled with prolonged corticosteroid therapy – sometimes at high doses – and biological therapies. In our unit, an incidence of mycobacterial infections of 5% has been observed in the last 10 years. Most of the patients with clinical infection were under treatment with prednisone (or equivalent dose of corticosteroids) >5 mg/day. We conclude that the need for chronic corticosteroid therapy should be balanced carefully in each patient, trying to reduce the dose and/or suspend it as soon as possible.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7375

SAT0408

SAFETY OF CONCOMITANT TREATMENT WITH DENOSUMAB AND OTHER BIOLOGICAL DRUGS

M. Garijo Bufort¹, M. Guerra González², C. Moriano Morales¹, C. Iñiguez Ubiaga¹, A. Crespo Golmar¹, I. González Fernández¹, A. López Robles¹, E. Díez Álvarez¹, C. Álvarez Castro¹, M. Martín Martínez¹, M.E. Vallejo Pascual³, T. Pérez Sandoval¹. ¹Rheumatology Department of the University Health Care Complex of León; ²Hospital Pharmacy of the University Health Care Complex of León; ³University of León, León, Spain

Background: Denosumab (DB) is a monoclonal antibody to RANK ligand that, like all biological drugs, can be associated with an increased risk of infections. However, there are few studies concerning the risk of infection in these patients treated concomitantly with DB and other biologic drugs.

Objectives: This study aims at determining whether the treatment with biological drugs and DB combined is associated with an increased risk of adverse effects in patients with autoimmune diseases.

Methods: Retrospective observational study of patients treated with DB combined with other biological drugs at the Hospital of León between 2010–2017. For proper patient selection, the data obtained from the medical prescription program of primary care and the data from the registry of outpatients and walk-in patients of hospital pharmacy were cross-referenced.

To determine the increased risk, a control group of patients treated both with bisphosphonates (BF) and with biological agents was selected.

The data collected in both groups were: age, sex, diagnosis, comorbidities and other prescribed drugs. Infection, tumour or other adverse effects appeared three months, six months, one year and two years after starting the concomitant treatment. When performing the statistical analysis, it was analysed the time elapsed until the first adverse effect appeared.

Results: A total n of 28 patients was registered. 16 were treated with BF and biological agents, and 12 were treated with DB and other biological drugs. The prevalence of women was higher in both groups (87.5% BF, 91.7% DB). The mean age at the beginning of the concomitant treatment was similar, being 69.1±8.5 years in the BF group and 69.7±7.1 years in the DB group. All patients treated with DB were diagnosed with RA. Regarding the comorbidities, it seems that those patients treated with DB had fewer CVRF than those treated with BF (68.8% HBP in BF versus 50% in DB, 37.5% dyslipidaemia in BF versus 33.3% in DB). The biological drugs prescribed to be used concomitantly with DB were: 49.7% anti-TNFα, 33.3% rituximab, 8.3% abatacept and 8.3% tocilizumab.

In addition, there were no significant differences regarding the application time of the concomitant treatment with biological agents in the BF (35.7±26.7 months) and DB (58.6±43.7 months) groups; being in both groups similar. By comparing both groups, it is observed that those patients treated concomitantly with DB and other biological drugs, have more infections and these appear earlier in time than in patients treated with BF and biological agents (p<0.005). Only one patient in the DB group had a tumour of pulmonary nature as an adverse effect.

There were no differences in the appearance of adverse effects in patients with other comorbidities or concomitant treatments.

Conclusions: It seems that the treatment of DB combined with other biological drugs is associated with a greater number of adverse effects, mainly caused by infections, and having an earlier appearance.

More studies and a larger sample would be necessary to confirm this association and to be able to prove the relationship between comorbidities and the use of other concomitant drugs with the appearance of adverse effects.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7526

SAT0409

AEROCOCCUS URINAE: FIRST REPORT OF SEPTIC OLIGOARTHRITIS AND SYSTEMATIC REVIEW OF AN EMERGING GERM IN MUSCULOSKELETAL INFECTIONS

M. Greco¹, Í. Rúa-Figueroa¹, S. Ghigione², E. Santana Medina³, J.C. Quevedo Abeledo¹, C. Rodríguez-Lozano¹, I. Altabás¹. ¹Rheumatology Department, Hospital Universitario de Gran Canaria Dr. Negrín; ²Radiology Department, Complejo Hospitalario Universitario Insular Materno Infantil; ³Radiology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain

Background: Aerococcus are bacteria not generally included in lists of musculoskeletal infections (MSK-I). They have been misidentified using standard techniques and can be detected by the sequencing of 16S rRNA (16S rDNA-PCR). Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) has shown to be reliable.¹

Objectives: To describe and analyse all documented cases of musculoskeletal infections caused by Aerococcus urinae and other Aerococcus sp.

Methods: In the framework of the study of a 63-years-old man with septic oligoarthritis caused by Aerococcus urinae (AU) (isolated in 2 synovial fluid samples), a systematic review was conducted to analyse all documented cases of aerococcal MSK-I (until December 2017); other manifestations of interest present in our case were also considered.